medroxyprogesterone acetate · Pfizer · updated June 2026
Depo-Provera, the long-acting birth-control shot, faces thousands of lawsuits alleging that long-term use raises the risk of meningioma (a brain tumor). The FDA has added a meningioma warning to the label.
This page is general information about ongoing litigation and FDA safety actions — not medical or legal advice, and not a statement that Depo-Provera caused any injury. Allegations described here are claims that have not been proven in court. Always consult a licensed professional.
Plaintiffs allege Pfizer failed to warn that repeated, long-term use of the medroxyprogesterone acetate shot increases the risk of developing a meningioma.
The FDA updated the Depo-Provera label to add a meningioma warning, reflecting cases reported with long-term use.
As of mid-2026, several thousand meningioma claims are consolidated in a federal MDL, with the first trial scheduled for December 2026. Reports in June 2026 indicate Pfizer agreed to settle claims filed in the MDL — so intake deadlines may apply.